Skip to main content
. Author manuscript; available in PMC: 2021 Oct 28.
Published in final edited form as: Ocul Surf. 2020 May 26;19:157–168. doi: 10.1016/j.jtos.2020.05.009

Figure 4: Novel strategies suppressing Th17 to limit ocular surface inflammation.

Figure 4:

Multiple promising therapeutic strategies aim to ameliorate ocular surface inflammation by regulating the differentiation, activation, migration or effector responses of Th17 cells.